India plans new bulk drug licence regime, supplier database to fix accountability
Proposal aims to build a database of bulk drug traders, improve traceability of imported raw materials, over 70% of which come from China, and allow regulators to identify and hold accountable specific dealers involved in supply of substandard inputs in India’s $50-billion pharmaceutical market.
Proposal aims to build a database of bulk drug traders, improve traceability of imported raw materials, over 70% of which come from China, and allow regulators to identify and hold accountable specific dealers involved in supply of substandard inputs in India’s $50-billion pharmaceutical market.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
